Physician profile
Daniel R Morgan
NPI 1154310811
$1,397.69
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $65.56 · 2021: $129 · 2022: $227 · 2023: $50.85 · 2024: $141 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.64 | 2019-2023 | |
| Medtronic, INC. | $171.07 | 2021-2024 | Interstim |
| Lupin INC. | $157.00 | 2019-2020 | |
| Novo Nordisk INC | $124.09 | 2022 | |
| Biogen, INC. | $96.42 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $91.30 | 2019-2022 | |
| Evofem Biosciences, INC. | $89.76 | 2022 | |
| Sage Therapeutics, LLC | $61.68 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $59.15 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $37.74 | 2019 | |
| Smith+Nephew, INC. | $27.51 | 2021 | |
| Therapeuticsmd, INC. | $27.46 | 2019 | |
| Allergan, INC. | $26.00 | 2019-2020 | |
| Covidien LP | $23.87 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.